Carmot to Receive Royalty Payments Upon Sales of Amgen’s FDA Approved First-in-class KRAS G12C Inhibitor, LUMAKRAS™ (sotorasib); Further Demonstrates the Value of Carmot’s Therapeutic Platform

BERKELEY, Calif.--(BUSINESS WIRE)--Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary therapeutic platform, Chemotype Evolution (CE), to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today that in connection with the recent U.S. Food and Drug Administration (FDA) approval and commercial launch of Amgen’s...

Click to view original post